In contrast, due to the minimal G1T38 compound in the plasma at 24 hours, the bone marrow seem to have more time to recover from CDK4/6 inhibition between doses suggesting that continuous daily dosing may be achievable in cancer patients. This evidence concerns the gene CDK4 and cancer.